BRPI0606790A2 - anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna. - Google Patents

anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.

Info

Publication number
BRPI0606790A2
BRPI0606790A2 BRPI0606790-5A BRPI0606790A BRPI0606790A2 BR PI0606790 A2 BRPI0606790 A2 BR PI0606790A2 BR PI0606790 A BRPI0606790 A BR PI0606790A BR PI0606790 A2 BRPI0606790 A2 BR PI0606790A2
Authority
BR
Brazil
Prior art keywords
antibody
fragment
isolated
composition
antigen binding
Prior art date
Application number
BRPI0606790-5A
Other languages
English (en)
Inventor
Donnna Ambrosino
Susan Schonhoff
Charles Rupprecht
William D Thomas Jr
Robert Mandell
Gregory J Barcock
Original Assignee
Univ Massachusetts E Ct S For
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts E Ct S For filed Critical Univ Massachusetts E Ct S For
Publication of BRPI0606790A2 publication Critical patent/BRPI0606790A2/pt
Publication of BRPI0606790B1 publication Critical patent/BRPI0606790B1/pt
Publication of BRPI0606790C1 publication Critical patent/BRPI0606790C1/pt
Publication of BRPI0606790C8 publication Critical patent/BRPI0606790C8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
    • C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

ANTICORPO HUMANO ISOLADO OU PORçãO DE LIGAçãO DE ANTìGENO DO MESMO, POLIPEPTìDEO ISOLADO, COMPOSIçãO, áCIDO NUCLEICO ISOLADO, VETOR DE EXPRESSãO, CéLULA HOSPEDEIRA, VACINA CONTRA A RAIVA, KIT, USO DE UM ANTICORPO MONOCLONAL HUMANO ISOLADO OU PORçãO DE LIGAçãO DE ANTIGENO DO MESMO, OU DE UMA QUANTIDADE EFICAZ DE UMA COMPOSIçãO, METODO PARA IDENTIFICAR UM ANTICORPO OU FRAGMENTO DO MESMO, ANTICORPO OU FRAGMENTO DO MESMO, E, GLICOPROTEINA. Os anticorpos monoclonais humanos que especificamente se ligam ao vírus da raiva, porções de ligação de antígeno dos mesmos, e métodos de fabricar e usar tais anticorpos e porções de ligação de antígeno dos mesmos para tratar o vírus da raiva em um paciente, são aqui fomecidos.
BRPI0606790A 2005-02-02 2006-02-02 anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, composição, vetor de expressão, microrganismo transgênico, célula hospedeira procariótica, kit, e, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, ou de uma composição BRPI0606790C8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64951205P 2005-02-02 2005-02-02
PCT/US2006/003644 WO2006084006A1 (en) 2005-02-02 2006-02-02 Human antibodies against rabies and uses thereof

Publications (4)

Publication Number Publication Date
BRPI0606790A2 true BRPI0606790A2 (pt) 2009-07-14
BRPI0606790B1 BRPI0606790B1 (pt) 2018-10-09
BRPI0606790C1 BRPI0606790C1 (pt) 2019-08-06
BRPI0606790C8 BRPI0606790C8 (pt) 2021-05-25

Family

ID=36589118

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606790A BRPI0606790C8 (pt) 2005-02-02 2006-02-02 anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, composição, vetor de expressão, microrganismo transgênico, célula hospedeira procariótica, kit, e, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antígeno do mesmo, ou de uma composição

Country Status (16)

Country Link
US (4) US7727532B2 (pt)
EP (1) EP1851315B1 (pt)
CN (2) CN101133158B (pt)
BR (1) BRPI0606790C8 (pt)
CA (1) CA2596697C (pt)
DK (1) DK1851315T3 (pt)
ES (1) ES2453973T3 (pt)
HR (1) HRP20140271T1 (pt)
ME (1) ME01785B (pt)
MX (1) MX2007009273A (pt)
PL (1) PL1851315T3 (pt)
PT (1) PT1851315E (pt)
RS (1) RS53239B (pt)
SI (1) SI1851315T1 (pt)
WO (1) WO2006084006A1 (pt)
ZA (1) ZA200707339B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
SI1851315T1 (sl) * 2005-02-02 2014-06-30 University Of Massachusetts Humana protitelesa proti steklini in njihova uporaba
MX2009004027A (es) * 2006-10-20 2009-09-28 Schering Corp Anticuerpos anti factor de crecimiento endotelial vascular completamente humanos y metodos de uso.
CN101235086B (zh) * 2007-02-02 2011-06-15 吉林圣元科技有限责任公司 重组人抗狂犬病毒抗体
US20110118446A1 (en) * 2007-09-28 2011-05-19 The General Hospital Corporation Methods and compositions for antibody production
CN101812130B (zh) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗狂犬病毒糖蛋白中和性抗体(RVFab5)
CN101812131B (zh) * 2010-05-06 2012-07-04 中国疾病预防控制中心病毒病预防控制所 人源抗狂犬病毒糖蛋白中和性抗体(RVFab8)
EP2630242B1 (en) 2010-10-19 2017-08-02 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services, Identification of antibodies specific for lyssaviruses
EP3556774B1 (en) 2011-03-11 2024-01-03 Beth Israel Deaconess Medical Center Inc. Anti-cd40 antibodies and uses thereof
WO2013048130A2 (ko) * 2011-09-30 2013-04-04 (주)셀트리온 광견병 바이러스를 중화시킬 수 있는 결합 분자
CN103374070B (zh) * 2012-04-24 2016-01-27 中国科学院上海生命科学研究院 一种抗狂犬病毒的结合分子2f5
CN103374069B (zh) * 2012-04-24 2015-06-03 中国科学院上海生命科学研究院 一种抗狂犬病毒的结合分子2e1
BR112016001192A2 (pt) * 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
CN103954777A (zh) * 2014-05-20 2014-07-30 北京凯思百奥科技发展有限公司 一种狂犬病病毒单克隆抗体及其应用
LT3220947T (lt) * 2014-11-18 2020-12-28 Humabs Biomed S.A. Antikūnai, galintys neutralizuoti pasiutligės virusą ir kitus lisavirusus bei jų panaudojimas
CN104722449A (zh) * 2015-04-09 2015-06-24 京东方科技集团股份有限公司 胶涂布头、涂胶设备及触控显示面板的制备方法
WO2016200189A1 (ko) * 2015-06-10 2016-12-15 (주)셀트리온 광견병 바이러스 g 단백질의 에피토프 및 이에 특이적으로 결합하는 광견병 바이러스 중화 결합 분자
US10450367B2 (en) * 2015-08-13 2019-10-22 University Of Massachusetts Human antibodies against rabies and uses thereof
KR20250007054A (ko) 2015-09-04 2025-01-13 프리마토프 테라퓨틱스 인크. 인간화 항-cd40 항체 및 그의 용도
ZA201604024B (en) * 2015-09-26 2017-08-30 Serum Institute Of India Pvt Ltd Improved feeding strategies and purification processes for monoclonal antibody production
RU2661028C2 (ru) * 2016-11-11 2018-07-11 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф.Гамалеи" Министерства здравоохранения Российской Федедерации Фармацевтическая композиция для пассивной иммунизации против бешенства, фармацевтический набор, способ применения фармацевтического набора
US20200131251A1 (en) * 2016-12-23 2020-04-30 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
CN108359640B (zh) * 2018-01-31 2020-12-01 武汉枢密脑科学技术有限公司 一种标记全脑区神经网络结构的狂犬病毒、其制备和应用
WO2019227039A1 (en) * 2018-05-24 2019-11-28 Lankenau Institute For Medical Research Compositions comprising antibodies to rabies virus and the uses thereof
CN111171145B (zh) * 2020-01-21 2021-11-05 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒单克隆抗体、制备方法及用途
CA3190707A1 (en) * 2020-08-28 2022-03-03 Torigen Pharmaceuticals, Inc. Immune memory enhanced preparations and uses thereof
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
CN117771365B (zh) * 2023-12-07 2025-07-04 兰州生物制品研究所有限责任公司 一种抗狂犬病病毒组合单克隆抗体制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7847094A (en) * 1993-09-30 1995-04-18 Thomas Jefferson University Oral vaccination of mammals
US5840300A (en) * 1995-09-11 1998-11-24 Trustees Of The University Of Pennsylvania Methods and compositions comprising single chain recombinant antibodies
US20040013672A1 (en) * 2000-05-16 2004-01-22 Thomas Jefferson University Recombinant antibodies, and compositions and methods for making and using the same
IL152825A (en) * 2000-05-16 2009-07-20 Univ Jefferson Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods
US7115717B2 (en) * 2001-05-18 2006-10-03 Kirin Beer Kabushiki Kaisha Anti-TRAIL-R antibodies
WO2005023849A2 (en) * 2003-09-04 2005-03-17 Crucell Holland B.V. Antigenic peptides of rabies virus and uses thereof
SI1851315T1 (sl) 2005-02-02 2014-06-30 University Of Massachusetts Humana protitelesa proti steklini in njihova uporaba

Also Published As

Publication number Publication date
ES2453973T3 (es) 2014-04-09
CA2596697C (en) 2019-04-09
DK1851315T3 (en) 2014-03-24
PT1851315E (pt) 2014-03-25
EP1851315A1 (en) 2007-11-07
HK1104060A1 (en) 2008-01-04
ME01785B (me) 2014-09-20
MX2007009273A (es) 2008-02-19
BRPI0606790C1 (pt) 2019-08-06
ZA200707339B (en) 2014-04-30
BRPI0606790B1 (pt) 2018-10-09
CN101133158B (zh) 2012-12-05
US7727532B2 (en) 2010-06-01
SI1851315T1 (sl) 2014-06-30
RS53239B (sr) 2014-08-29
CA2596697A1 (en) 2006-08-10
US20150315266A1 (en) 2015-11-05
US20130039926A1 (en) 2013-02-14
CN102936284A (zh) 2013-02-20
CN101133158A (zh) 2008-02-27
PL1851315T3 (pl) 2014-06-30
US20110008360A1 (en) 2011-01-13
EP1851315B1 (en) 2013-12-25
US8226952B2 (en) 2012-07-24
US20090041777A1 (en) 2009-02-12
HRP20140271T1 (hr) 2014-05-23
BRPI0606790C8 (pt) 2021-05-25
WO2006084006A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
BRPI0507433C1 (pt) anticorpo monoclonal recombinante ou sua parte de ligação ao antígeno, composição, ácido nucleico isolado, vetor de expressão, e, kit
BRPI0816117B8 (pt) anticorpo monoclonal isolado ou fragmento do mesmo, composiçãofarmacêutica, kit para tratamento de desordens relacionadas com colesterol, e, uso de uma proteína de ligação de antígeno ou de um anticorpo monoclonal ou fragmento do mesmo
BR112012003064B8 (pt) anticorpo ou fragmento de ligação de antígeno do mesmo, combinação que os compreende, método de detecção de infecção por rsv, moléculas de ácido nucléico, e método de produção de um anticorpo ou fragmento de ligação de antígeno do mesmo
BR112013004579A2 (pt) proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9
CO6630164A2 (es) Proteinas que se unen al tnf-a
BRPI0513798A (pt) anticorpos anti-cd154
BRPI0418766A (pt) anticorpos e moléculas derivadas destes que se ligam às proteìnas steap-1
BR112013004266A8 (pt) anticorpos anti-ox40 e métodos de uso dos mesmos.
BRPI0416603A (pt) anticorpo que se liga ao receptor interleucina-4 (il-4) humano
NO20085131L (no) Lyofiliserte preparater av anti-EGFR-antistoffer
NO20082559L (no) Humane monoklonale antistoffer mot protein tyrosin kinase 7 (PTK7) og fremgangsmater for anvendelse av anti-PTK7 antistoffer
BRPI0612273B8 (pt) anticorpo de ligação a il-1 beta ou fragmento de ligação a il-1 beta do mesmo, ácido nucleico, vetor, e, composição
BR112012028326A2 (pt) anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos
EP2352523A4 (en) IMPROVED ANTI-CD19 ANTIBODIES
NO20083793L (no) Antistoffer mot amyloid-beta peptid
ATE503770T1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
WO2020172621A8 (en) Cd33 antibodies and methods of using the same to treat cancer
IL187321A (en) Host cell specific binding molecules encoding monoclonal antibodies capable of neutralizing viruses, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
MX2024009860A (es) Anticuerpos monoclonales humanos que se dirigen ampliamente a los coronavirus
BRPI0906997A2 (pt) Proteína, uso da proteína combinante ou fragmento da mesma, método para induzir uma resposta imune em um individuo, método para tratar um paceinte, construção de ácido nicleico, vetor de ezpressão o ucélula hospedeira, vacina, anticorpo, e, composição farmaceutica
MX348152B (es) Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos.
BRPI0808940A8 (pt) anticorpo humano ou fragmento de ligação do mesmo, antígeno, polinucleotídeo, vetor, célula hospedeira, método para preparar um anticorpo ou um fragmento de ligação ou cadeia(s) de imunoglobulina do mesmo, anticorpo, cadeia de imunoglobulina ou um fragmento de ligação do mesmo, composição, usos do anticorpo ou fragmento de ligação, de um antígeno, de um polinucleotídeo, de um vetor, ou de uma célula, e de uma molécula de ligação a antígeno tumoral, método para clonagem molecular de um anticorpo, e, kit para o diagnóstico de um tumor

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2492 DE 09/10/2018, QUANTO AO NOME DE UM DOS INVENTORES.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/10/2018, OBSERVADAS AS CONDICOES LEGAIS. (CO) REFERENTE A RPI 2533 DE 23/07/2019, QUANTO AO ITEM (73) NOME DO TITULAR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF